ClinicalTrials.gg
RecruitingNCT07395076IMMUNORESP2Updated May 14, 2026

Study of the Immunological Pathophysiological Mechanisms Associated With Acute Respiratory Distress Syndrome

An observational study in Acute Respiratory Distress Syndrome (ARDS), sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Respiratory Distress Syndrome by Assistance Publique - Hôpitaux de Paris — 16 open to participants now, 16 under way, 2 of them phase 3. Respiratory Distress Syndrome · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
9th of 11
50 · median 80
Started
2026
with 3 others
Observational
11 of 33
6 open now
Primary completion
2029-05
later than 13 of 15 live
Registered
31st of 33
by date

Among the 33 studies in Respiratory Distress Syndrome by Assistance Publique - Hôpitaux de Paris, this one is the 9th largest by planned enrollment of the 11 observational ones that give a count, is one of 4 that started in 2026, is one of 11 observational ones, reaches primary completion later than 13 of the 15 other live ones, and was the 31st registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

16 of the 33 studies in Respiratory Distress Syndrome by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Respiratory Distress Syndrome by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

About 10% of patients admitted to the ICU suffer from ARDS, with a mortality rate of around 35-45%. The lack of therapeutic innovation in ARDS can be partly explained by the heterogeneity of patients included under this definition.

A better understanding of the pathophysiological mechanisms underlying the different patient phenotypes is essential to develop new therapeutic strategies.

Objectives:

To characterize the inflammatory profile of patients with ARDS using circulating biomarkers and single-cell RNA sequencing of pulmonary immune cells.

The investigators hypothesize that there is a correlation between the profile of serum biomarkers (inflammatory sub-phenotypes), the transcriptome of pulmonary immune cells.

Briefly the experimental scheme is as follow:

  • Population: patients with ARDS under invasive mechanical ventilation in the ICU.
  • Intervention:

    1. Determination of the inflammatory subphenotype on circulatory inflammatory biomarkers.
    2. Characterization of inflammation by single cell RNA sequencing on lung immune cells collected on broncho-alveolar fluid.
Read the detailed description

Acute Respiratory Distress Syndrome (ARDS) is the most severe form of pulmonary failure. It is defined by bilateral radiologic opacities associated with severe hypoxemia, confirmed by a PaO₂/FiO₂ ratio \<300 in the absence of a cardiac cause. About 10% of patients admitted to the Intensive Care Units (ICU) develop ARDS, and this diagnosis is associated with an in-hospital mortality of 35-45%. Like sepsis, ARDS leads to long-term complications. It is associated with physical deconditioning and reduced quality of life that can persist up to five years after the episode. Survivors are readmitted to the ICU within a year in 30% of cases. Moreover, excess mortality among ARDS survivors is attributable, in nearly one-third of cases, to a new acute respiratory infection.

The lack of therapeutic advances in ARDS has led researchers to better characterize patients with this condition. Different subphenotypes have been identified based on plasma inflammatory biomarker profiles, which are associated with distinct responses to treatments (such as corticosteroids, ventilatory management, and fluid management) and variable prognoses. The mechanisms underlying these different biological subphenotypes remain unknown. To further explore this concept, it is necessary to precisely identify subpopulations of patients who present with similar clinical features but distinct biological phenotypes driven by unique pathophysiological mechanisms. Establishing these different ARDS endotypes is essential for the development of innovative and targeted therapeutic strategies.

Our hypothesis is that the different biological subphenotypes of ARDS reflect distinct profiles of pulmonary immune cell populations, representing a first step toward understanding ARDS endotypes.

Identifying these endotypes is a crucial step for developing targeted and innovative therapeutic strategies aimed at reducing ARDS-related morbidity and mortality. This is the objective of the proposed project.

03

Conditions studied

  • Acute Respiratory Distress Syndrome (ARDS)

Keywords

  • acute respiratory distress syndrome
  • subphenotypes
  • ADRS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Hospitalized patients in intensive care unit suffering from mechanically ventilated ARDS as defined by Matthay et al.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ARDS risk factors: bacterial or viral pneumonia, extrapulmonary infection, major trauma, transfusion, inhalation injury, or shock.
  • Pulmonary edema not explained by a cardiogenic cause or volume overload.
  • Onset of respiratory symptoms within \<7 days.
  • Bilateral pulmonary involvement on chest X-ray, CT scan, or ultrasound.
  • PaO₂/FiO₂ ≤ 300 assessed with PEEP ≥ 5 cmH₂O.

Exclusion criteria

Exclusion Criteria:

  • ARDS with intubation for more than 48 hours.
  • to bronchoscopy: effective anticoagulation, dual antiplatelet therapy, thrombocytopenia \<50 G/L.
  • Pre-existing immunodeficiency: active solid tumor or remission \<5 years, active hematologic or remission \<5 years, systemic disease (even without specific treatment), solid organ or bone marrow transplant, infection with CD4 \<200/mm³.
  • Cardiac arrest with a poor prognosis (NSE >60, malignant EEG, diffuse ischemia on imaging, loss of trunk reflexes).
  • Patients \<18 year-old
  • Patients under legal guardianship, curatorship, or deprived of liberty.
  • Ongoing pregnancy.
  • Patients without social security coverage.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Single cell RNA sequencing of pulmonary immune cells

    Single cell RNA sequencing of pulmonary immune cells collected during a bronchoalveolar lavage at inclusion.

    Time frame: At baseline

Secondary outcomes

  1. Mortality

    Mortality rate at day 90

    Time frame: At day 90

  2. Mortality

    Mortality rate at one year

    Time frame: 1 year

  3. Time without respiratory support

    Number of days alive without mechanical ventilation on day 28 after inclusion or on discharge from intensive care if this occurs before the 28th day

    Time frame: At day 28

  4. Length of stay in intensive care

    Number of days in intensive care.

    Time frame: From inclusion to ICU discharge up to 1 year

  5. Number of secondary infections

    Rate of secondary infections defined as a new prescription of antibiotics

    Time frame: At day 90

  6. Number of secondary infections

    Rate of secondary infections defined as a new prescription of antibiotics

    Time frame: 1 year

  7. Impact perceived on quality of life

    Quality of life assessed though the SF-12 questionnaire on the phone.

    Time frame: At day 90

  8. Impact perceived on quality of life

    Rate of secondary infections defined as a new prescription of antibiotics

    Time frame: 1 year

  9. Dsypnea scale

    Dyspnea scale assessed through mMRC questionnaire on the phone

    Time frame: At day 90

  10. Dsypnea scale

    Dyspnea scale assessed through mMRC questionnaire on the phone

    Time frame: 1 year

  11. Organ failure

    SOFA score assessment

    Time frame: At baseline

  12. Organ failure

    SOFA score assessment

    Time frame: At day 7.

  13. Need for vasopressor

    Need for vasopressor (epinephrine or norepinephrine)

    Time frame: At baseline

  14. Vasopressor free days

    Number of days alive without vasopressors on day 28 after inclusion or on discharge from intensive care if this occurs before the 28th day.

    Time frame: At day 28 or at discharge from intensive care

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for May 2029, 36 months after the start.

Of 228 non-industry observational studies under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 36 months is above that.

Counting every sponsor, half of 234 studies reached it within 24 months; a quarter within 12 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2026
First posted
Feb 9, 2026
StartActual
May 11, 2026
Primary completionEst.
May 11, 2029
CompletionEst.
May 11, 2029
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07395076
Responsible party
Sponsor
First posted
Feb 9, 2026
Start date
May 11, 2026
Primary completion
May 11, 2029 (estimated)
Completion
May 11, 2029 (estimated)
Last update
May 14, 2026

Study contacts

Pierre-Louis BLOT, MD
Contact
pierre-louis.blot@aphp.fr
+331049956565
Benjamin Chousterman, MD PhD
Contact
benjamin.chousterman@aphp.fr
+330149958518

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion